NetworkNewsBreaks – ABcann Global Corporation (TSXV: ABCN) Extends Role of “Father of Marijuana Research” Raphael Mechoulam
In a news release issued early Tuesday, ABcann Global Corporation (TSXV: ABCN) announced that Raphael Mechoulam has agreed to extend his role as an advisor to the company. Aaron Keay, CEO and director of ABcann, spoke to the importance of this agreement in the news release. “Professor Mechoulam’s experience in medicinal cannabis is an invaluable resource for ABcann as we enter the most aggressive growth stage in the company’s history,” he stated. “The Company has invested heavily to build and extend its early leadership in advanced pharmaceutical-grade cannabis production. Professor Mechoulam’s advice, guidance, and unmatched expertise in the field has played a major role in achieving this.” Mechoulam is an Israeli organic chemist who is commonly regarded as the “Father of Marijuana Research.” Working in the field for more than five decades, some of his most noteworthy research accomplishments include determining the chemical structure of cannabidiol (CBD) in 1963, isolating and synthesizing tetrahydrocannabinol (THC) in 1964 and elucidating the structure of the brain’s first endogenous cannabinoid in 1992.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer